Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biomark DiagnosticsSTU:20B 27 Quick Ratio is 0.99 as of Mar. 2026, which is 296% above its 10-year median of 0.25. GuruFocus rates STU:20B with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Biomark Diagnostics ranks worse than 68.54% on this metric.
Biomark Diagnostics has a quick ratio of 0.99. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Biomark Diagnostics's Quick Ratio or its related term are showing as below:
STU:20B'
s Quick Ratio Range Over the Past 10 Years
Min: 0.03 Med: 0.25 Max: 2.14
Current: 0.99
During the past 13 years, Biomark Diagnostics's highest Quick Ratio was 2.14. The lowest was 0.03. And the median was 0.25.
STU:20B's Quick Ratio is ranked worse than 68.54% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.74
vs STU:20B: 0.99
Biomark Diagnostics (STU:20B) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Biomark Diagnostics Quick Ratio Related Terms
Biomark Diagnostics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Biomark Diagnostics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Biomark Diagnostics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomark Diagnostics Quick Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Biomark Diagnostics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Biomark Diagnostics's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomark Diagnostics (STU:20B) has a Quick Ratio of 0.99 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Biomark Diagnostics and its competitors. This is 296% above median its historical median of 0.25. Over the past decade, Biomark Diagnostics' Quick Ratio has ranged from 0.03 to 2.14. According to the industry distribution chart, Biomark Diagnostics ranks #146 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 68.5%.
Is Biomark Diagnostics' Quick Ratio too high?
Biomark Diagnostics' current Quick Ratio of 0.99 is 296% above median its 10-year median of 0.25. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 2.14. The Medical Diagnostics & Research industry median Quick Ratio is 1.74. Biomark Diagnostics' value of 0.99 is 43.1% below this industry median. Based on the distribution chart, Biomark Diagnostics ranks #146 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Biomark Diagnostics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Biomark Diagnostics' Quick Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biomark Diagnostics ranks #146 out of 213 companies for Quick Ratio. This places Biomark Diagnostics in the lower half of its industry. The industry median Quick Ratio is 1.74. Biomark Diagnostics' value of 0.99 is 43.1% below this benchmark. Historically, Biomark Diagnostics' own Quick Ratio has ranged from 0.03 to 2.14 over the past decade. While the company's 10-year median is 0.25 vs. the industry median of 1.74, Biomark Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Diagnostics & Research company?
The median Quick Ratio among Medical Diagnostics & Research companies is 1.74, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biomark Diagnostics's current Quick Ratio of 0.99 is 43.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Biomark Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Quick Ratio is 1.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomark Diagnostics's current Quick Ratio is 0.99, which is 296% above median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomark Diagnostics stock overvalued right now?
Biomark Diagnostics (STU:20B) has a current Quick Ratio of 0.99. The current Quick Ratio is 0.99, which is 296% above median its 10-year median of 0.25 and 43.1% below the Medical Diagnostics & Research industry median of 1.74. Biomark Diagnostics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Biomark Diagnostics (STU:20B), the current Quick Ratio is 0.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
27GF Score
Get the complete analysis for STU:20B
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:20B has been successfully added to your 
